摘要
目的:探讨安罗替尼辅助治疗非小细胞肺癌(NSCLC)的效果及对转化生长因子-β1(TGF-β1)、基质金属蛋白酶2(MMP2)水平的影响。方法:选取2020年3月—2023年11月泗阳医院收治的80例NSCLC患者作为研究对象,根据治疗方法的不同分为A组(n=40)和C组(n=40)。A组使用培美曲塞+顺铂治疗,C组同时使用安罗替尼辅助治疗。比较两组临床疗效、肿瘤标志物、TGF-β1、MMP2水平、生存质量、不良反应情况。结果:C组的治疗有效率高于A组,差异有统计学意义(P<0.05);治疗后C组细胞角蛋白19片段抗原(CYFRA21-1)、糖类抗原125(CA125)、癌胚抗原(CEA)均低于A组,差异有统计学意义(P<0.05);治疗后C组TGF-β1、MMP2水平均低于A组,差异有统计学意义(P<0.05);治疗后C组肺癌生存质量评价量表(FACT-L)、卡氏功能状态评分(KPS)均高于A组,差异有统计学意义(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论:安罗替尼辅助治疗NSCLC的效果显著,能够降低患者的肿瘤标志物及TGF-β1、MMP2水平,改善生存质量,安全性好。
Objective:To investigate the effect of Antirotinib in the adjuvant treatment of non-small cell lung cancer(NSCLC)and its effect on the levels of transforming growth factor-β1(TGF-β1)and matrix metalloproteinase 2(MMP2).Method:According to different treatments,80 patients with NSCLC in the hospital from March 2020 to November 2023 were divided into group A(n=40)and group C(n=40).Group A was treated with Pemetrexed and Cisplatin,while group C was treated with Anlotinib.The clinical efficacy,tumor markers,TGF-β1,MMP2 levels,quality of life and adverse reactions were compared between the two groups.Result:The therapeutic effective rate of group C was higher than that of group A(P<0.05).After treatment,cytokeratin 19 fragment antigen(CYFRA21-1),carbohydrate antigen 125(CA125)and carcino-embryonic antigen(CEA)in group C were lower than those in group A(P<0.05).After treatment,the levels of TGF-β1 and MMP2 in group C were lower than those in group A(P<0.05),the lung cancer Quality of Life of Functional Assessment Cancer Therapy-Lung(FACT-L)and KPS scores in group C were higher than those in group A(P<0.05).There was no significant difference in the comparison of reactions between the two groups(P>0.05).Conclusion:Anlotinib has a significant effect in the adjuvant treatment of NSCLC,which can reduce the tumor markers,TGF-β1 and MMP2 levels of patients,improve the quality of life and have good safety.
作者
张艳
严雨潇
ZHANG Yan;YAN Yuxiao(Siyang Hospital,Siyang 223700,China;不详)
出处
《中外医学研究》
2024年第30期50-53,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
